Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 53

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Type 1 diabetes mellitus

Not recruiting

Study on Insulin Lispro and Insulin Human for Managing Blood Sugar After Meals in Type 1 Diabetes Patients with Different Gastric Emptying Rates

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Human (Rdna)
  • Sponsor:Katholisches Klinikum Bochum gGmbH

Hypophosphatasia

Not recruiting

Study on ALXN1850 for Adolescents and Adults with Hypophosphatasia Not Previously Treated with Asfotase Alfa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALXN1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Cachexia

Not recruiting

Study of ponsegromab for patients with cancer cachexia and elevated GDF-15 levels

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Coeliac disease

Not recruiting

Study on the Effects of KAN-101 and Sodium Chloride in Adults with Celiac Disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:KAN-101
  • Sponsor:Kanyos Bio Inc.

Hypercholesterolaemia

Not recruiting

Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Cardiovascular disorder+1

Not recruiting

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lerodalcibep
  • Sponsor:Lib Therapeutics LLC

Phenylketonuria

Not recruiting

Study Comparing Sepiapterin and Sapropterin for Treating Phenylketonuria in Patients Aged 2 Years and Older

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:(S)-2-Amino-6-(2-Hydroxypropanoyl)-7,8-Dihydropteridin-4(3H)-One
  • Sponsor:PTC Therapeutics Inc.

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 for Patients with Thyroid Eye Disease Who Did Not Respond to Previous Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Acromegaly

Not recruiting

Study of long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Hydrochloride
  • Sponsor:Camurus AB

Hepato-lenticular degeneration

Not recruiting

Study on Gene Therapy with VTX-801 and Copper (64Cu) Chloride for Adults with Wilson's Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human Atp7B
  • Sponsor:Vivet Therapeutics

Metabolic disorder

Not recruiting

Study on the Effects of GLM101 for Patients with PMM2-CDG

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Alfa-D-Mannopyranosyl Phosphate Dipotassium
  • Sponsor:Glycomine Inc.

Mucopolysaccharidosis I

Not recruiting

Study on the Effectiveness and Safety of OTL-203 for Patients with Hurler Syndrome (MPS-IH) Compared to Standard Treatment with Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Orchard Therapeutics (Europe) Limited

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.